This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish (read more).

Resources - Articles

Return to Sender – Clinical Trial Returns

Article courtesy of ICT (International Clinical Trials) – Oct 2014

Trial planning inevitably focuses on the set-up and timely delivery of studies – and less on later logistics such as the return of unused drugs. But neglecting this issue can lead to scope creep and unexpected costs, which is why early dialogue and decisions on returns are essential.

In recent years, the pharmaceutical industry has witnessed tremendous change in the way it is expected to deliver new drugs to market. This has been driven by several factors.

The industry has faced head-on the prospect of ‘the patent cliff’, losing about $290 billion in revenue from branded prescription medications going off-patent. At the same time,drug development timelines are under constant attack, with speed to market paramount to success. As such, innovation and cost-effi ciency is crucial ….

Read More:

October 12, 2015


Expansion of High Potent Tableting and Powder Modification Capacity

Investment in new technologies at PCI’s global manufacturing Center of Excellence in Tredegar, Wales, to double highly potent tableting capacity... View Article

PCI Welcomes New Chief Financial Officer and SVP, Serge Dupuis

PCI is pleased to welcome Serge Dupuis as Senior Vice President and Chief Financial Officer. Serge’s appointment supports PCI’s continued... View Article

x